Department of Radiology, the First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
NCT Number: NCT01333618
It has been demonstrated that implantation of inferior vena cava filter was safe and effective in the prevention or reduction of fatal pulmonary thromboembolism in numerous clinical researches. When acute deep venous thrombosis need transcatheter thrombolysis, transfemoral Günther Tulip Filter implantation could avoid catheter across the Günther Tulip Filter. Although incidence of significant filter tilting (>10°) is not high (13%-16%), severe tilting of the Günther Tulip Filter may be associated with difficulty or sometimes impossibility of retrieval. It has been reported that a simple technique of keeping tension of the delivery system may prevent significant tilting of the transjugular Günther Tulip Filter in an in-vitro study. But no clinical study of prevention transfemoral Günther Tulip Filter from tilting has been reported. The investigators conducted a randomized, controlled study to test whether the introducer curving technique is useful to decrease the extent of tilting of transfemoral Günther Tulip Filter.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Shenyang, Liaoning, 110001, China
The study was designed as a double-blind randomized controlled trial, with research assessors and patients intended to be blind to the intervention status. The staff members performing the assessment were not involved in implementing any aspect of the intervention. 108 patients were randomized to accept curving introducer Günther Tulip Filter and transcatheter thrombolysis or straight introducer Günther Tulip Filter and transcatheter thrombolysis. The assessments include the tilting angle between the axes of inferior vena cava and Günther Tulip Filter after implantation; the tilting angle between the axes of inferior vena cava and Günther Tulip Filter before retrieval; the fluoroscopy time of Günther Tulip Filter retrieval; the rate of retrieval hook adhering vascular wall; the success rate of retrieval.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark) The amplitude of introducer curvature was 5°-15° less than the angle between the inferior vena cave axis and the approached iliac vein axis and the distance between the vertex of the curved angle and the hook of the filter was 2-4cm less than the distance between the level of the renal vein confluence and the furcation of inferior vena cave.
The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark)
Time frame: just after filter implantation (up to 24 hours)
Time frame: just before filter retrieval (up to 90 days)
Time frame: just after filter retrieval(up to 90 days)
Time frame: just after filter retrieval(up to 90 days)
Time frame: just after filter retrieval(up to 90 days)
China Medical University, China
Other
Introducer Curving Technique for Tilt of Transfemoral Günther Tulip Inferior Vena Cava Filter:A Randomized Double-Blind Comparison
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06495996
Cardiovascular Diseases, Deep Venous Thrombosis
Newport Beach, California, United States
View Trial DetailsNCT03195777
Cardiovascular Diseases, Deep Venous Thrombosis
Boston, Massachusetts, United States
View Trial DetailsNCT01828697
Cardiovascular Diseases, Deep Venous Thrombosis
New York, United States
View Trial DetailsNCT04452422
COVID-19, Cardiovascular Diseases
Strasbourg, France
View Trial Details